Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Dianthus Therapeutics, Inc. - Common Stock (NQ:DNTH)

20.38 -0.24 (-1.16%)
Streaming Delayed Price Updated: 11:23 AM EDT, May 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Dianthus Therapeutics, Inc. - Common Stock

< Previous 1 2 Next >
Dianthus Therapeutics Completes Enrollment of Phase 2 MaGic Trial of DNTH103 in Generalized Myasthenia Gravis With Top-Line Results Expected in September
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Dianthus Therapeutics to Participate in Two Upcoming Investor Events
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Friday's pre-market session: top gainers and losers
As the US market prepares to open on Friday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
Forecasting The Future: 5 Analyst Projections For Dianthus Therapeutics
Via Benzinga
Evaluating Dianthus Therapeutics: Insights From 5 Financial Analysts
Via Benzinga
A Glimpse Into The Expert Outlook On Dianthus Therapeutics Through 4 Analysts
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY 2024 Financial Results
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Dianthus Therapeutics Strengthens Strategic Commercial Leadership With Appointment of John C. King as Chief Commercial Officer and Welcomes Sujay Kango, A Seasoned Commercial Leader, to Board of Directors
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Dianthus Therapeutics to Participate in Two Upcoming Investor Conferences
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Expert Ratings For Dianthus Therapeutics
Via Benzinga
Navigating 4 Analyst Ratings For Dianthus Therapeutics
Via Benzinga
Dianthus Therapeutics to Webcast Presentations at Two Investor Conferences
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Dianthus Therapeutics to Webcast Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Powell Industries Reports Weak Sales, Joins Target, QuidelOrtho And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
What 5 Analyst Ratings Have To Say About Dianthus Therapeutics
Via Benzinga
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Dianthus Therapeutics to Participate in Three Upcoming Healthcare Investor Conferences
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Dianthus Therapeutics to Participate in Three Healthcare Investor Conferences in September
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Ulta Beauty Reports Downbeat Results, Joins Elastic And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
DNTH Stock Earnings: Dianthus Therapeutics Beats EPS, Beats Revenue for Q2 2024
DNTH stock results show that Dianthus Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 10th Congress of the European Academy of Neurology (EAN)
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Dianthus Therapeutics Announces FDA Clearance to Initiate Phase 2 Trial of DNTH103 in Multifocal Motor Neuropathy (MMN)
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Dianthus Therapeutics to Participate in the Jefferies Global Healthcare Conference
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
DNTH Stock Earnings: Dianthus Therapeutics Misses EPS, Beats Revenue for Q1 2024
DNTH stock results show that Dianthus Therapeutics missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Dianthus Therapeutics to Participate in the Bank of America Securities 2024 Health Care Conference
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.